Concepedia

Publication | Open Access

Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial

DOIFull Paper Access

52

Citations

29

References

2023

Year

Ajay K. Nooka, Adam D. Cohen, Hans C. Lee, Ashraf Badros, Attaya Suvannasankha, Natalie S. Callander, Al‐Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N. Libby,
Cancer

Abstract

This final analysis of DREAMM-2 confirms that in patients with triple-class refractory RRMM, single-agent belamaf results in durable and clinically meaningful responses with a manageable safety profile.

References

YearCitations

Page 1